bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”), Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) announce that all required regulatory approvals to complete the previously announced acquisition of the Company by Carlyle and SK Capital have been received. No further regulatory approvals are required to complete the transaction.
Read the full article: Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio //
Source: https://www.businesswire.com/news/home/20250505620164/en/Carlyle-and-SK-Capital-Receive-All-Required-Regulatory-Approvals-to-Complete-the-Acquisition-of-bluebird-bio